

LcS Topic: Inflammatory bowel disease (IBD)

Lactobacillus casei Shirota (LcS) is the unique probiotic strain in Yakult

For further information visit our website: www.yakult.co.uk/hcp
 Contact the UK science team on science@yakult.co.uk or 0208 8427 600.
 Contact the Irish science team on science@yakult.ie or 01 804 7695

Last updated 22 October 2014

General

Heat-killed probiotic bacteria differentially regulate colonic epithelial cell production of human b-defensin-2: dependence on inflammatory cytokines.

Habil N, Abate W, Beal J *et al* (2014) *Beneficial Microbes* **5(4)**:483-495.

[Free paper] [PubMed]

Dysregulated circulating dendritic cell function in ulcerative colitis is partially restored by probiotic strain *Lactobacillus casei* Shirota.

Mann ER, You J, Horneffer-van der Sluis V *et al* (2013) *Mediators of Inflammation* Article ID 573576.

[Free paper] [PubMed]

Beneficial effects of *Lactobacillus casei* in ulcerative colitis: a pilot study.

Mitsuyama K, Matsumoto S, Yamasaki H *et al* (2008) *Journal of Clinical Biochemistry & Nutrition* **43 (Suppl 1)**: 78-81 (2008).

A component of polysaccharide peptidoglycan complex on *Lactobacillus* induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer.

Matsumoto S, Hara T, Nagaoka M, Mike A *et al* (2009) *Immunology* **128 (suppl 1)**: e170-e180.

[PubMed]

Anti-inflammatory effects of probiotic *Lactobacillus casei* strain Shirota in chronic intestinal inflammatory disorders.

Matsumoto S (2008) *International Journal of Probiotics and Prebiotics* **3(3)**: 149-152.

[Journal available on request]

High dose probiotic and prebiotic co-therapy for remission induction of active Crohn's disease.

Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K *et al* (2007) *Journal of Gastroenterology & Hepatology* **22**: 1199-204.

[PubMed]

Probiotic *Lactobacillus*-induced improvement in murine chronic inflammatory disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells.

Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N, Suzuki A, Sata M (2005) *Clinical and Experimental Immunology* **140(3)**: 417-426.

[Free article] [PubMed]

Probiotic effects of *Lactobacillus casei* on DSS-induced ulcerative colitis in mice.

Herias MV, Koninkx JFJG, Vos JG, Huis In't Veld JHJ, van Dijk JE (2005) *International Journal of Food Microbiology* **2**: 143-155.

[PubMed]

Further papers relevant to IBD

1) Cancer (further papers cited in LcS Topic: *Cancer*)

Probiotics and cancer – from *in vitro* to human studies

Rowland I (2008) *International Journal of Probiotics & Prebiotics* **3(3)**: 165-168.

[Journal available on request]

Relationship between the *in vitro* response of dendritic cells to *Lactobacillus* and prevention of tumorigenesis in the mouse.

Takagi A, Ikemura H, Matsuzaki T, Sato M, Nomoto K *et al* (2008) *Journal of Gastroenterology* **43**: 661-669.

[PubMed]

Randomized trial of dietary fiber and *Lactobacillus casei* administration for prevention of colorectal tumours.

Ishikawa H, Akedo I, Otani T, Suzuki T, Nakamura T *et al* (2005) *International Journal of Cancer* **116**: 762-767.

[Reprint available on request] [PubMed]

The enhancing effect of oral *Lactobacillus casei* on the immunologic activity of colon cancer patients.

Sawamura A, Yamaguchi Y, Toge T, Nagata N, Ikeda H *et al* (1994) *Biotherapy* **8(12)**: 1567-1572.

2) Antibiotic-associated diarrhoea (further papers cited in LcS Topic: *Gut-related infections*)

Effects of antibiotic therapy on the gastrointestinal microbiota and the influence of *Lactobacillus casei*.

Pirker A, Stockenhuber A, Remely M *et al* (2012) *Food & Agricultural Immunology*

doi:10.1080/09540105.2012.689816.

[Abstract]

The potential of probiotic fermented milk products in reducing risk of antibiotic-associated diarrhoea and *Clostridium difficile* disease.

Lewis JN, Thomas LV & Weir W (2009) *International Journal of Dairy Technology* **62(4)**:461-471.

[Reprint available on request]

Prevention of *C difficile* Related Disease with Prophylactic Probiotic.

Weir W. (Oral presentation). Topics in Infection XXXV (Barts & the London), 30th January 2009.

Preventing diarrhoea associated with antibiotics using a probiotic *Lactobacillus casei* preparation.

Stockenhuber A, Kamhuber C, Leeb G, Adelmann K, Prager E, Mach K & Stockenhuber F (2008) *Gut* **57(Suppl II)**: A20 (2008).

3) Immune function benefit (further papers cited in LcS Topic: *Immune function*)

Well-controlled proinflammatory cytokine responses of Peyer's patch cells to probiotic *Lactobacillus casei*

Chiba Y, Shida K, Nagata S, Wada M, Bian L, Wang C, Shimizu T, Yamashiro Y, Kiyoshima-Shibata J, Nanno M, Nomoto K (2010) *Immunology* **130(3)**: 352-362

[PubMed]

